Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $43
UBS analyst Trung Huynh maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and adjusts the target price from $52 to $43.According to TipRanks data, the analyst has a success rate of 75.5%
Express News | Bristol-Myers Squibb Co : UBS Cuts Target Price to $43 From $47
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $41
Barclays analyst Carter Gould maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate of 57.7%
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Cuts Target Price to $37
Morgan Stanley analyst Terence Flynn maintains $Bristol-Myers Squibb(BMY.US)$ with a sell rating, and adjusts the target price from $40 to $37.According to TipRanks data, the analyst has a success
Morgan Stanley Sticks to Its Sell Rating for Bristol-Myers Squibb (BMY)
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating
Bristol-Myers Squibb (BMY) has an average hold rating and a price target range of $37 to $75, according to analysts polled by Capital IQ.Price: 41.08, Change: -0.04, Percent Change: -0.10
Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know
Bristol-Myers Squibb Company (NYSE:BMY) Is a Favorite Amongst Institutional Investors Who Own 78%
Express News | Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $41
Bristol-Myers Squibb Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 -0.15% Barclays $43 → $41 Maintains Equal-Weight 04/26/2024 16.9% BMO Capital $55 → $48
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity
Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at
Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43
Bristol-Myers Squibb (BMY) has an average hold rating and price target range of $37 to $75, according to analysts polled by Capital IQ.Price: 40.85, Change: -0.01, Percent Change: -0.02
Express News | Bristol-Myers Squibb Company : Barclays Cuts Target Price to $41 From $43
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $41
Barclays analyst Carter Gould maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and adjusts the target price from $51 to $41.According to TipRanks data, the analyst has a success rate of 57
Citi Research's AI Hedge Stocks - Part II
How Is The Market Feeling About Bristol-Myers Squibb?
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has risen 5.63% since its last report. The company recently reported that it has 30.29 million shares sold short, which is 1.5% of all
Bristol-Myers Squibb Options Spot-On: On July 8th, 80,884 Contracts Were Traded, With 779.33K Open Interest
On July 8th ET, $Bristol-Myers Squibb(BMY.US)$ had active options trading, with a total trading volume of 80,884 options for the day, of which put options accounted for 49.96% of the total transaction
Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day